Evidence map›Paper›PMID 19043530›Full record

ArticleTranslational oncology2008

Enzastaurin, an inhibitor of PKCbeta, Enhances Antiangiogenic Effects and Cytotoxicity of Radiation against Endothelial Cells.

Aaron C Spalding, Benjamin D Zeitlin, Kari Wilder-Romans, Mary E Davis, Jacques E Nor, Theodore S Lawrence, Edgar Ben-Josef

Open access · goldAbstract read
In one paragraph

Article in Translational oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Aaron C SpaldingThe University of Michigan Medical School, Department of Radiation Oncology, Ann Arbor, MI 48109-0010, USA.
Benjamin D Zeitlin
Kari Wilder-Romans
Mary E Davis
Jacques E Nor
Theodore S Lawrence
Edgar Ben-Josef
University of Michigan–Ann Arbor · US

Funding

PKC Beta Inhibition With Gemcitabine And Radiation In Pancreas CancerR03CA127050 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BEN-JOSEF, EDGAR · 2007 to 2008
$148k
NCI NIH HHS R03 CA127050
6 · The paper itself

Abstract

purposeAngiogenesis plays an important role in pancreas cancer pathobiology. Pancreatic tumor cells secrete vascular endothelial growth factor (VEGF), activating endothelial cell protein kinase C beta (PKCbeta) that phosphorylates GSK3beta to suppress apoptosis and promote endothelial cell proliferation and microvessel formation. We used Enzastaurin (Enz) to test the hypothesis that inhibition of PKCbeta results in radiosensitization of endothelial cells in culture and in vivo. MATERIALS/

methodsWe measured PKCbeta phosphorylation, VEGF pathway signaling, colony formation, and capillary sprout formation in primary human dermal microvessel endothelial cells (HDMECs) after Enz or radiation (RT) treatment. Microvessel density and tumor volume of human pancreatic cancer xenografts in nude mice were measured after treatment with Enz, RT, or both.

resultsEnz inhibited PKCbeta and radiosensitized HDMEC with an enhancement ratio of 1.31 +/- 0.05. Enz combined with RT reduced HDMEC capillary sprouting to a greater extent than either agent alone. Enz prevented radiation-induced GSK3beta phosphorylation of serine 9 while having no direct effect on VEGFR phosphorylation. Treatment of xenografts with Enz and radiation produced greater reductions in microvessel density than either treatment alone. The reduction in microvessel density corresponded with increased tumor growth delay.

conclusionsEnz-induced PKCbeta inhibition radiosensitizes human endothelial cells and enhances the antiangiogenic effects of RT. The combination of Enz and RT reduced microvessel density and resulted in increased growth delay in pancreatic cancer xenografts, without increase in toxicity. These results provide the rationale for combining PKCbeta inhibition with radiation and further investigating such regimens in pancreatic cancer.

Identifiers

PMID19043530
PMCPMC2582168
OpenAlexW1999617811

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.